常见产品
Common Products
相关产品
CAS:1854126-42-3|Chloroquine-d5 diphosphate
- 产品货号:DT2025061405
- 发布时间:2025-06-05
- 产品CAS :1854126-42-3
- 产品规格:mg(更多包装需求请咨询客服)
- 产品纯度:≥98%
- 产品货期:现货下单后48小时内发货,定制产品4-8周。
- 运输条件:顺丰常规运输
产品详情
货号:DT2025061405
CAS:1854126-42-3
规格:mg(更多包装需求请咨询客服)
纯度:≥98%
生产商:试剂家
生物活性:Chloroquine-d5 (diphosphate) is the deuterium labeled Chloroquine (phosphate). Chloroquine phosphate is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine phosphate is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine phosphate is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC50=1.13 μM)[1][2][3][4].
IC50 & Target:Plasmodium
TLRs
体外研究(In Vitro):Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
试剂家 has not independently confirmed the accuracy of these methods. They are for reference only.
Chloroquine-d5 diphosphate 相关抗体:
IRF3 Antibody
Toll-Like Receptor 4 Antibody
CD4 Antibody
Toll-Like Receptor 3 Antibody
TLR2 Antibody
TARBP2 Antibody (YA1433)
SAMHD1 Antibody (YA1542)
Toll-Like Receptor 2 Antibody (YA1932)
TRIF Antibody (YA2263)
TIRAP Antibody (YA2589)
SV40 T Antigen Antibody (YA3256)
Toll-Like Receptor 9 Antibody (YA3321)
CLEC12A Antibody (YA1419)
Toll-Like Receptor 7 Antibody (YA2514)
Tat SF1 Antibody (YA2886)
Toll-Like Receptor 5 Antibody (YA3265)
分子量:520.89
Formula:C18H27D5ClN3O8P2
CAS 号:1854126-42-3
非标记 CAS:50-63-5
中文名称:磷酸氯喹 d5 (二磷酸盐)
运输条件:Room temperature in continental US; may vary elsewhere.
储存方式:Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
Data Sheet (534 KB)
产品使用指南 (1538 KB)
参考文献
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
[Content Brief]
[2]. Said A, et al. Chloroquine promotes IL-17 production by CD4+ T cells via p38-dependent IL-23 release by monocyte-derived Langerhans-like cells. J Immunol. 2014 Dec 15;193(12):6135-43.
[Content Brief]
[3]. Tuomela J, et al. Chloroquine has tumor-inhibitory and tumor-promoting effects in triple-negative breast cancer. Oncol Lett. 2013 Dec;6(6):1665-1672.
[Content Brief]
[4]. Mohamed FE, et al. Effect of toll-like receptor 7 and 9 targeted therapy to prevent the development of hepatocellular carcinoma. Liver Int. 2014 Jul 2. doi: 10.1111/liv.12626.
[Content Brief]
[5]. Wang M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271.
[Content Brief]
[6]. Colson P, et al. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents. 2020;55(4):105932.
[Content Brief]
[7]. Savarino A, et al. The anti-HIV-1 activity of chloroquine. J Clin Virol. 2001;20(3):131-135.
[Content Brief]
在线留言
欢迎您访问“试剂家 | 纳米靶向科研平台”官方网站,请留下您的需求,我们会派专业人员及时与您联系,并为您提供相应的产品方案。